title: Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?
abstract: Biomarkers, or more specifically molecular markers, can detect biochemical changes associated with disease processes and drug effects before histopathological and pathophysiological changes occur. Multiplexing technologies such as high-performance liquid chromatography/mass spectrometry (LC-MS) allow for the measurement of molecular marker patterns that confer significantly more information than the measurement of a single parameter alone. The use of multiplexing assays for drug development, and as diagnostic tools, is attractive but will require regulatory review and approval and thus requires validation following regulatory guidances. Multiplexing assays always constitute a compromise. The number of analytes that can reasonably be included in a mass spectrometry-based multiplexing assay depend on the physico-chemical properties of the analytes and their integration into a single assay in terms of extraction, HPLC separation, ionization conditions and mass spectrometry detection. Another aspect includes biomedical considerations such as the differences in physiological concentrations of analytes, the required concentration range, and how much variability is acceptable before the clinical utility of a marker is negatively affected. Regulatory considerations include validation and quality control during sample analysis. Current bioanalytical regulatory guidelines have mostly been developed for single drug compounds and are not always adequate for multiplexing molecular marker assays that often quantify endogenous compounds. Specific guidances for multiplexing assays should be developed. Even if it is possible to integrate a wide variety and large number of analytes into a multiplexing assay, it should always be taken into consideration that a set of shorter, more specialized assays, may offer a more manageable and efficient alternative.
authors: iC42 Clinical Research & Development, Department of Anesthesiology, University of Colorado, Aurora, Colorado 80045, United States.
authors: Uwe
authors: U
authors: Christians
authors: Jacek
authors: J
authors: Klepacki
authors: Touraj
authors: T
authors: Shokati
authors: Jost
authors: J
authors: Klawitter
authors: Jelena
authors: J
authors: Klawitter
keywords: biomarkers; liquid chromatography- mass spectrometry; metabolomics; multiplexing; regulatory aspects; validation
references: Clin Pharmacol Ther. 2001 Mar;69(3):89-95
references: 11240971
references: Pharmacogenomics. 2006 Jul;7(5):773-82
references: 16886901
references: Rapid Commun Mass Spectrom. 2011 Feb 28;25(4):463-8
references: 21259353
references: Toxicology. 2008 Mar 20;245(3):219-23
references: 18280028
references: Rapid Commun Mass Spectrom. 2005;19(1):47-56
references: 15570573
references: Anal Biochem. 2007 Jun 15;365(2):230-9
references: 17475198
references: Clin Chem. 2007 Mar;53(3):489-97
references: 17259231
references: Nat Biotechnol. 2006 Aug;24(8):971-83
references: 16900146
references: Expert Rev Mol Diagn. 2006 Jul;6(4):575-85
references: 16824031
references: Adv Cancer Res. 2007;96:269-98
references: 17161683
references: AAPS J. 2007 Mar 23;9(1):E105-8
references: 17408233
references: Environ Mol Mutagen. 2007 Jun;48(5):354-8
references: 17567848
references: Bioessays. 2006 May;28(5):534-45
references: 16615085
references: Am J Transplant. 2008 Feb;8(2):267-70
references: 18093264
references: Br J Pharmacol. 2008 Feb;153(4):646-56
references: 17876307
references: Curr Pharm Biotechnol. 2011 Jul;12(7):1053-66
references: 21466457
references: Clin Chem. 2003 Jul;49(7):1041-4
references: 12816898
references: Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1023-38
references: 19611406
references: Pharm Res. 2005 Apr;22(4):499-511
references: 15846456
references: Clin Chem Lab Med. 2003 Oct;41(10):1289-98
references: 14580154
references: Clin Pharmacol Ther. 2007 Jan;81(1):104-7
references: 17186007